Vigabatrin
SABRIL, VIGADRONE, VIGAFYDE, VIGPODER
Anti-epileptic Agent
NADAC/unit
N/A
No Shortage
Tier 1: 75.4%
PA Req: 327.7%
16 Manufacturers
18 ANDAs
Vigabatrin prevents seizures by stabilizing electrical activity in the brain.
Active Shortages
2025-10-16 Discontinuation of the manufacture of the drug, Pyros Pharmaceuticals, Inc.
Market Intelligence
2024-01-17 Class I Recall: InvaGen Pharmaceuticals, Inc.
2023-09-06 Class III Recall: Lundbeck LLC
Generic Manufacturers
ALKEM LABORATORIES LTDAMNEAL PHARMACEUTICALS OF NEW YORK LLCANNORA PHARMA PRIVATE LTDAUCTA PHARMACEUTICALS INCAUROBINDO PHARMA LTDCARNEGIE PHARMACEUTICALS LLCDEXCEL PHARMA TECHNOLOGIES LTDDR REDDYS LABORATORIES LTDHIKMA PHARMACEUTICALS USA INCINVAGEN PHARMACEUTICALS INCLUNDBECK PHARMACEUTICALS LLCMSN LABORATORIES PRIVATE LTDPH HEALTH LTDPYROS PHARMACEUTICALS INCTEVA PHARMACEUTICALS USAUPSHER SMITH LABORATORIES LLCZYDUS LIFESCIENCES GLOBAL FZE
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.